메뉴 건너뛰기




Volumn 29, Issue 9, 2011, Pages 573-584

Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab

Author keywords

Breast cancers; Chemotherapy; Outcomes research

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

EID: 80054859025     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.616251     Document Type: Article
Times cited : (18)

References (40)
  • 1
    • 84856950170 scopus 로고    scopus 로고
    • Genentech, Inc. (trastuzumab).South San Francisco, CA: Genentech, Inc. Accessed October 7, 2010
    • Genentech, Inc. Prescribing Information for Herceptin (trastuzumab).South San Francisco, CA: Genentech, Inc, 2009. http://www.gene.com/gene/products/ information/pdf/herceptinprescribing.pdf. Accessed October 7, 2010.
    • (2009) Prescribing Information for Herceptin
  • 2
    • 34347395733 scopus 로고    scopus 로고
    • Trastuzumab - Mechanism of action and use in clinical practice
    • DOI 10.1056/NEJMra043186
    • Hudis CA. Trastuzumab-Mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51. (Pubitemid 47026733)
    • (2007) New England Journal of Medicine , vol.357 , Issue.1 , pp. 39-51
    • Hudis, C.A.1
  • 4
    • 0032850677 scopus 로고    scopus 로고
    • Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
    • Cobleigh MA, Vogel CL, Tripathy D, Nicholas RJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648. (Pubitemid 29415219)
    • (1999) Journal of Clinical Oncology , vol.17 , Issue.9 , pp. 2639-2648
    • Cobleigh, M.A.1    Vogel, C.L.2    Tripathy, D.3    Robert, N.J.4    Scholl, S.5    Fehrenbacher, L.6    Wolter, J.M.7    Paton, V.8    Shak, S.9    Lieberman, G.10    Slamon, D.J.11
  • 6
    • 0346017700 scopus 로고    scopus 로고
    • Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel
    • DOI 10.1200/JCO.2003.12.109
    • Leyland-Jones B, Gelman K, Ayoub J-P, Arnold A, Verma S, Dias R, Ghahramani P. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003;21:3965-3971. (Pubitemid 46606210)
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.21 , pp. 3965-3971
    • Leyland-Jones, B.1    Gelmon, K.2    Ayoub, J.-P.3    Arnold, A.4    Verma, S.5    Dias, R.6    Ghahramani, P.7
  • 11
    • 84856973156 scopus 로고    scopus 로고
    • Surveillance, Epidemiology, and End Results (SEER) Program) SEER.*Stat Database: Incidence-SEER 17 Nov Sub (1973-2006 varying) - Linked To County Attributes-Total U.S., 1969-2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission
    • Surveillance, Epidemiology, and End Results (SEER) Program) (www.seer.cancer.gov) SEER.*Stat Database: Incidence-SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2008 Sub (1973-2006 varying) - Linked To County Attributes-Total U.S., 1969-2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission.
    • (2008) Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases
  • 12
    • 0038478965 scopus 로고    scopus 로고
    • Overview of SEER-Medicare data: Content research applications and generalizability to the United States elderly population
    • Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Medical Care 2002;40(suppl):IV-3-IV-18.
    • (2002) Medical Care , vol.40
    • Warren, J.L.1    Klabunde, C.N.2    Schrag, D.3    Bach, P.B.4    Riley, G.F.5
  • 13
    • 64549145652 scopus 로고    scopus 로고
    • National Cancer Institute NCI Internet]. Bethesda MD:NCI Accessed October 7, 2010.
    • National Cancer Institute (NCI).Overview of the SEER program[ Internet]. Bethesda, MD:NCI, 2010. http://seer.cancer.gov/ about. Accessed October 7, 2010.
    • (2010) Overview of the SEER program
  • 14
    • 84856947660 scopus 로고    scopus 로고
    • National Cancer Institute (NCI). SEER-Medicare: Internet]. Bethesda MD: NCI Accessed October 7, 2010
    • National Cancer Institute (NCI). SEER-Medicare: How the SEER & Medicare data are Linked [Internet]. Bethesda, MD: NCI, 2010. http://healthservices.cancer.gov/seermedicare/overview/linked.html. Accessed October 7, 2010.
    • (2010) How the SEER & Medicare data are Linked
  • 16
    • 41549150295 scopus 로고    scopus 로고
    • Ten-year survival and cost following breast cancer recurrence: Estimates from SEER-Medicare data
    • DOI 10.1111/j.1524-4733.2007.00226.x
    • Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winder EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-Medicare data. Value in Health 2008;11:213-220. (Pubitemid 351473603)
    • (2008) Value in Health , vol.11 , Issue.2 , pp. 213-220
    • Stokes, M.E.1    Thompson, D.2    Montoya, E.L.3    Weinstein, M.C.4    Winer, E.P.5    Earle, C.C.6
  • 17
    • 78649684237 scopus 로고    scopus 로고
    • (PMIC).ICD-9-CM, 6th ed. Los Angeles, CA: Practice Management Information Corporation
    • Practice Management Information Corporation (PMIC).ICD-9-CM, 6th ed. Los Angeles, CA: Practice Management Information Corporation, 2005.
    • (2005) Practice Management Information Corporation
  • 20
    • 84856972877 scopus 로고    scopus 로고
    • National Cancer Institute NCI internet]. Bethesda MD: NCI Accessed July 12, 2010.
    • National Cancer Institute (NCI).Procedure codes for SEERMedicare analysis [internet]. Bethesda, MD: NCI, 2010. http://healthservices.cancer.gov/ seermedicare/considerations/procedure-codes.html. Accessed July 12, 2010.
    • (2010) Procedure codes for Seer Medicare analysis
  • 21
    • 78649525226 scopus 로고    scopus 로고
    • Res DAC Research Data Assistance Center Minneapolis, MN: ResDAC
    • ResDAC Research Data Assistance Center. CMS 301: Using SEER/Medicare data for research. Minneapolis, MN: ResDAC.
    • CMS 301: Using SEER/Medicare data for research
  • 23
    • 0034531923 scopus 로고    scopus 로고
    • Development of a comorbidity index using physician claims data
    • DOI 10.1016/S0895-4356(00)00256-0, PII S0895435600002560
    • Klabunde CN, Potosky AL, Legler JM,Warren JL.Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-1267. (Pubitemid 32007842)
    • (2000) Journal of Clinical Epidemiology , vol.53 , Issue.12 , pp. 1258-1267
    • Klabunde, C.N.1    Potosky, A.L.2    Legler, J.M.3    Warren, J.L.4
  • 24
    • 0003612597 scopus 로고    scopus 로고
    • Fritz A, Ries L, (eds.). 3rd edition Bethesda, MD: Cancer Statistics Branch, SurveillanceProgram, Div of Cancer Control and Pop Sciences, National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Deptartment of Health and Human Services Accessed October 7, 2010
    • Fritz A, Ries L, (eds.). SEER Program Code Manual, 3rd edition. Bethesda, MD: Cancer Statistics Branch, SurveillanceProgram, Div of Cancer Control and Pop Sciences, National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Deptartment of Health and Human Services, 1998. http://seer.cancer.gov/manuals/codeman.pdf. Accessed October 7, 2010.
    • (1998) SEER Program Code Manual
  • 25
    • 79953713795 scopus 로고    scopus 로고
    • National Cancer Institute NCI Bethesda MD: Author. Accessed May 25
    • National Cancer Institute (NCI).SAS macro to remove unreliable diagnosis coding. Bethesda, MD: Author. http://healthservices. cancer.gov/seermedicare/ program/remove.ruleout.dxcodes.macro.txt. Accessed May 25, 2010.
    • (2010) SAS Macro to Remove Unreliable Diagnosis Coding
  • 26
    • 84856970118 scopus 로고    scopus 로고
    • SAS macro to calculate a comorbidity index for a patient with respect to cancer
    • National Cancer Institute (NCI). Accessed May 25
    • National Cancer Institute (NCI).SAS macro to calculate a comorbidity index for a patient with respect to cancer. NCI http://healthservices.cancer. gov/seermedicare/program/charlson.comorbidity.macro.txt. Accessed May 25, 2010.
    • (2010) NCI
  • 27
    • 0023092594 scopus 로고
    • A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
    • DOI 10.1016/0021-9681(87)90171-8
    • Charlson ME, Pompei P, Ales KL,MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40(5):373-383. (Pubitemid 17055592)
    • (1987) Journal of Chronic Diseases , vol.40 , Issue.5 , pp. 373-383
    • Charlson, M.E.1    Pompei, P.2    Ales, K.A.3    MacKenzie, C.R.4
  • 28
    • 0026639706 scopus 로고
    • Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
    • Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
    • (1992) J. Clin. Epidemiol. , vol.45 , pp. 613-619
    • Deyo, R.A.1    Cherkin, D.C.2    Ciol, M.A.3
  • 29
    • 0028227007 scopus 로고
    • A comparison of administrative versus clinical data: Coronary artery bypass surgery as an example
    • DOI 10.1016/0895-4356(94)90006-X
    • Romano PS, Roos LL, Luft HS, Jollis JG, Doliszny K. A comparison of administrative versus clinical data: coronary artery bypass surgery as an example. J Clin Epidemiol 1994;47:249-260. (Pubitemid 24109737)
    • (1994) Journal of Clinical Epidemiology , vol.47 , Issue.3 , pp. 249-260
    • Romano, P.S.1    Roos, L.L.2    Luft, H.S.3    Jollis, J.G.4    Doliszny, K.5
  • 30
    • 79952035882 scopus 로고    scopus 로고
    • Using claimsbased measures to predict performance status score in patients with lung cancer
    • Salloum RG, Smith TJ, Jensen GA, Elston Lafata J. Using claimsbased measures to predict performance status score in patients with lung cancer. Cancer 2010;117:1038-1048.
    • (2010) Cancer , vol.117 , pp. 1038-1048
    • Salloum, R.G.1    Smith, T.J.2    Jensen, G.A.3    Elston Lafata, J.4
  • 32
    • 0030862072 scopus 로고    scopus 로고
    • Estimating causal effects from large data sets using propensity scores
    • Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-763. (Pubitemid 27446562)
    • (1997) Annals of Internal Medicine , vol.127 , Issue.8 SUPPL. , pp. 757-763
    • Rubin, D.B.1
  • 33
    • 39349101029 scopus 로고    scopus 로고
    • Immortal time bias in pharmacoepidemiology
    • DOI 10.1093/aje/kwm324
    • Suissa S. Immortal time bias in pharmacoepidemiology. AmJ Epidemiol 2008;167:492-499. (Pubitemid 351264145)
    • (2008) American Journal of Epidemiology , vol.167 , Issue.4 , pp. 492-499
    • Suissa, S.1
  • 35
    • 78649829808 scopus 로고    scopus 로고
    • Comparative effectiveness of prostate cancer treatments: Evaluating statistical adjustments for confounding in observational data
    • Hadley J, Yabroff KR, Barrett MJ, Penson DF, Saigal CS, Potosky AL. Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst 2010;102:1780-1793.
    • (2010) J. Natl. Cancer Inst. , vol.102 , pp. 1780-1793
    • Hadley, J.1    Yabroff, K.R.2    Barrett, M.J.3    Penson, D.F.4    Saigal, C.S.5    Potosky, A.L.6
  • 37
    • 37049183697 scopus 로고
    • Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182. (Pubitemid 17231334)
    • (1987) Science , vol.235 , Issue.4785 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3
  • 38
    • 84856960931 scopus 로고    scopus 로고
    • Accessed October 7, 2010
    • Siegel J. Approval of biologics license application for Trastuzumab, 1998. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm091360.pdf. Accessed October 7, 2010.
    • (1998) Approval of Biologics License Application for Trastuzumab
    • Siegel, J.1
  • 40
    • 19344364880 scopus 로고    scopus 로고
    • Effects of chemotherapy and hormonal therapy for early breast cancer onrecurrence and 15-year survival: Anoverviewof the randomized trials
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer onrecurrence and 15-year survival: anoverviewof the randomized trials. Lancet 2005;365(9472):1687-1717.
    • (2005) Lancet , vol.365 , Issue.9472 , pp. 1687-1717


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.